Literature DB >> 9817185

Mechanism of progression of renal disease: current hemodynamic concepts.

C I Johnston1, J Risvanis, M Naitoh, I Tikkanen.   

Abstract

BACKGROUND: Hypertension, a known independent risk factor for end-stage renal failure, damages the kidney in multiple ways. It produces hemodynamic and mechanical stress, which may lead to glomerular endothelial dysfunction. Both of these mechanisms may lead to increased glomerular leakiness, hence proteinuria, which may damage the kidney further. Hypertension may also stimulate the production of vasoactive substances that, in turn, activate the production of cytokines and growth factors, leading to the production of extracellular matrix proteins. Thus, the progression of renal failure is related to both systemic and glomerular hemodynamic changes and to the activation of vasoactive hormones, growth factors and cytokines. THERAPY: To protect the kidney, we need to control or prevent the occurrence of these factors. Therapy with effective antihypertensive agents, such as angiotensin-converting enzyme inhibitors, has been shown to slow the progression of end-stage renal disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9817185

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  8 in total

1.  Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome.

Authors:  Zhuwen Yi; Zhihui Li; Xiao-Chuan Wu; Qing-Nan He; Xi-Qiang Dang; Xiao-Jie He
Journal:  Pediatr Nephrol       Date:  2006-05-06       Impact factor: 3.714

2.  Importance of blood pressure reduction for prevention of progression of renal disease.

Authors:  S C Textor; V J Canzanello
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

3.  The case for combining angiotensin-converting enzyme inhibitors and calcium-channel blockers.

Authors:  A A Taylor; S Sunthornyothin
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

4.  Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism.

Authors:  Jennifer M Sasser; Jennifer C Sullivan; Janet L Hobbs; Tatsuo Yamamoto; David M Pollock; Pamela K Carmines; Jennifer S Pollock
Journal:  J Am Soc Nephrol       Date:  2006-12-13       Impact factor: 10.121

5.  The African American Study of Kidney Disease and Hypertension (AASK): new findings.

Authors:  D A Sica; J G Douglas
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Jul-Aug       Impact factor: 3.738

Review 6.  Renal protection in diabetes: lessons from ONTARGET.

Authors:  Eberhard Ritz; Roland E Schmieder; Carol A Pollock
Journal:  Cardiovasc Diabetol       Date:  2010-10-01       Impact factor: 9.951

7.  Association of angiotensin-converting enzyme gene I/D polymorphism with steroid responsiveness in childhood nephrotic syndrome.

Authors:  P Prasun; N Prasad; G Tripathi; T Jafar; S Sharda; S Gulati; S Agrawal
Journal:  Indian J Nephrol       Date:  2011-01

8.  Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats.

Authors:  D J Kelly; Y Zhang; G Moe; G Naik; R E Gilbert
Journal:  Diabetologia       Date:  2007-09-08       Impact factor: 10.122

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.